Pravastatin ameliorates placental vascular defects, fetal growth, and cardiac function in a model of glucocorticoid excess

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 22, 2016, Pages 6265-6270

  Wyrwoll, Caitlin S ^a   Noble, June ^b   Thomson, Adrian ^b   Tesic, Dijana ^a   Miller, Mark R ^b   Rog Zielinska, Eva A ^b,c   Moran, Carmel M ^b   Seckl, Jonathan R ^b   Chapman, Karen E ^a,b   Holmes, Megan C ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

11 HSD2; Developmental programming; Fetal heart; Glucocorticoids; Placenta

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; GLUCOCORTICOID; PRAVASTATIN; VASCULOTROPIN; HSD11B2 PROTEIN, MOUSE; HYPOCHOLESTEROLEMIC AGENT; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY RESISTANCE; ARTICLE; BLOOD FLOW VELOCITY; CONTROLLED STUDY; FEMALE; FETUS ECHOGRAPHY; FETUS GROWTH; FETUS HEART; FETUS WEIGHT; GENE EXPRESSION; HEART FUNCTION; HEMODYNAMICS; MALE; MOUSE; NONHUMAN; PLACENTA DISORDER; PRIORITY JOURNAL; UMBILICAL VEIN; VASCULARIZATION; ANIMAL; C57BL MOUSE; FETAL GROWTH RETARDATION; GENETICS; HEART DISEASES; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PLACENTA DISEASES; PREGNANCY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ANIMALS; ANTICHOLESTEREMIC AGENTS; FEMALE; FETAL GROWTH RETARDATION; GLUCOCORTICOIDS; HEART DISEASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLACENTA DISEASES; PRAVASTATIN; PREGNANCY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84971422163     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1520356113     Document Type: Article

References (47)

1. Godfrey KM, Barker DJ (2001) Fetal programming and adult health. Public Health Nutr 4(2 B):611-624.
2. Fowden AL, Forhead AJ (2015) Glucocorticoids as regulatory signals during intrauterine development. Exp Physiol 100(12):1477-1487.
3. Wyrwoll CS, Mark PJ, Mori TA, Puddey IB, Waddell BJ (2006) Prevention of programmed hyperleptinemia and hypertension by postnatal dietary omega-3 fatty acids. Endocrinology 147(1):599-606.
4. Wyrwoll CS, Mark PJ, Mori TA, Waddell BJ (2008) Developmental programming of adult hyperinsulinemia, increased proinflammatory cytokine production, and altered skeletal muscle expression of SLC2A4(GLUT4) and uncoupling protein 3. J Endocrinol 198(3):571-579.
5. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR (1993) Glucocorticoid exposure in utero: New model for adult hypertension. Lancet 341(8841):339-341.
6. Lindsay RS, Lindsay RM, Edwards CR, Seckl JR (1996) Inhibition of 11-beta-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Hypertension 27(6):1200-1204.
7. Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR (1998) Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J Clin Invest 101(10):2174-2181.
8. O'Regan D, Kenyon CJ, Seckl JR, Holmes MC (2004) Glucocorticoid exposure in late gestation in the rat permanently programs gender-specific differences in adult cardiovascular and metabolic physiology. Am J Physiol Endocrinol Metab 287(5):E863-E870.
9. Hewitt DP, Mark PJ, Waddell BJ (2006) Glucocorticoids prevent the normal increase in placental vascular endothelial growth factor expression and placental vascularity during late pregnancy in the rat. Endocrinology 147(12):5568-5574.
10. Wyrwoll CS, Seckl JR, Holmes MC (2009) Altered placental function of 11betahydroxysteroid dehydrogenase 2 knockout mice. Endocrinology 150(3):1287-1293.
11. Brown RW, et al. (1996) The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology 137(2):794-797.
12. Burton PJ, Smith RE, Krozowski ZS, Waddell BJ (1996) Zonal distribution of 11 betahydroxysteroid dehydrogenase types 1 and 2 messenger ribonucleic acid expression in the rat placenta and decidua during late pregnancy. Biol Reprod 55(5):1023-1028.
13. Mairesse J, et al. (2007) Maternal stress alters endocrine function of the feto-placental unit in rats. Am J Physiol Endocrinol Metab 292(6):E1526-E1533.
14. O'Donnell KJ, et al. (2012) Maternal prenatal anxiety and downregulation of placental 11β-HSD2. Psychoneuroendocrinology 37(6):818-826.
15. Cottrell EC, Seckl JR, Holmes MC, Wyrwoll CS (2014) Foetal and placental 11β-HSD2: A hub for developmental programming. Acta Physiol (Oxf) 210(2):288-295.
16. Vaughan OR, Sferruzzi-Perri AN, Coan PM, Fowden AL (2013) Adaptations in placental phenotype depend on route and timing of maternal dexamethasone administration in mice. Biol Reprod 89(4):80.
17. Barker DJ, et al. (2012) The placental origins of sudden cardiac death. Int J Epidemiol 41(5):1394-1399.
18. Thornburg KL, O'Tierney PF, Louey S (2010) Review: The placenta is a programming agent for cardiovascular disease. Placenta 31(Suppl):S54-S59.
19. Kiserud T, Ebbing C, Kessler J, Rasmussen S (2006) Fetal cardiac output, distribution to the placenta and impact of placental compromise. Ultrasound Obstet Gynecol 28(2):126-136.
20. Shaut CA, Keene DR, Sorensen LK, Li DY, Stadler HS (2008) HOXA13 is essential for placental vascular patterning and labyrinth endothelial specification. PLoS Genet 4(5):e1000073.
21. Adams RH, et al. (2000) Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 6(1):109-116.
22. Barak Y, et al. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4(4):585-595.
23. Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G (2010) A new mouse model to explore therapies for preeclampsia. PLoS One 5(10):e13663.
24. Michelsohn AM, Anderson DJ (1992) Changes in competence determine the timing of two sequential glucocorticoid effects on sympathoadrenal progenitors. Neuron 8(3):589-604.
25. Corrigan N, Brazil DP, Auliffe FM (2010) High-frequency ultrasound assessment of the murine heart from embryo through to juvenile. Reprod Sci 17(2):147-157.
26. Rog-Zielinska EA, et al. (2013) Glucocorticoid receptor is required for foetal heart maturation. Hum Mol Genet 22(16):3269-3282.
27. Rubattu S, Volpe M (2001) The atrial natriuretic peptide: A changing view. J Hypertens 19(11):1923-1931.
28. Lu B, et al. (2012) Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models. Physiol Genomics 44(8):443-454.
29. Jozkowicz A, Dulak J, Piatkowska E, Placha W, Dembinska-Kiec A (2000) Ligands of peroxisome proliferator-activated receptor-gamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim Pol 47(4):1147-1157.
30. Bishop JE, Laurent GJ (1995) Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J 16(Suppl C):38-44.
31. Kotelevtsev Y, et al. (1999) Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest 103(5):683-689.
32. Barker DJ, Thornburg KL, Osmond C, Kajantie E, Eriksson JG (2010) The surface area of the placenta and hypertension in the offspring in later life. Int J Dev Biol 54(2-3):525-530.
33. Eriksson JG, Kajantie E, Thornburg KL, Osmond C, Barker DJ (2011) Mother's body size and placental size predict coronary heart disease in men. Eur Heart J 32(18):2297-2303.
34. Okada Y, et al. (2007) Complementation of placental defects and embryonic lethality by trophoblast-specific lentiviral gene transfer. Nat Biotechnol 25(2):233-237.
35. Kane AD, Herrera EA, Hansell JA, Giussani DA (2012) Statin treatment depresses the fetal defence to acute hypoxia via increasing nitric oxide bioavailability. J Physiol 590(2):323-334.
36. Kumasawa K, et al. (2011) Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA 108(4):1451-1455.
37. Ramma W, Ahmed A (2014) Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol 101-102:153-160.
38. Saad AF, et al. (2014) Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci 21(1):138-145.
39. Forbes K, et al. (2015) Statins inhibit insulin-like growth factor action in first trimester placenta by altering insulin-like growth factor 1 receptor glycosylation. Mol Hum Reprod 21(1):105-114.
40. Zarek J, et al. (2013) The transfer of pravastatin in the dually perfused human placenta. Placenta 34(8):719-721.
41. Nanovskaya TN, et al. (2013) Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol 209(4):373.e1-373.e5.
42. Giussani DA, et al. (2012) Developmental programming of cardiovascular dysfunction by prenatal hypoxia and oxidative stress. PLoS One 7(2):e31017.
43. Richter HG, et al. (2012) Ascorbate prevents placental oxidative stress and enhances birth weight in hypoxic pregnancy in rats. J Physiol 590(6):1377-1387.
44. Holmes MC, et al. (2006) The mother or the fetus? 11beta-hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids. J Neurosci 26(14):3840-3844.
45. Mu J, Adamson SL (2006) Developmental changes in hemodynamics of uterine artery, utero- and umbilicoplacental, and vitelline circulations in mouse throughout gestation. Am J Physiol Heart Circ Physiol 291(3):H1421-H1428.
46. Corstius HB, et al. (2005) Effect of intrauterine growth restriction on the number of cardiomyocytes in rat hearts. Pediatr Res 57(6):796-800.
47. Vandesompele J, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):RESEARCH0034.